 |
|
Improvement of Pyoderma Gangrenosum and Psoriasis Associated With Crohn Disease With Anti–Tumor Necrosis Factor  Monoclonal Antibody
Mei-Heng Tan, MD;
Marsha Gordon, MD;
Oscar Lebwohl, MD;
James George, MD;
Mark G. Lebwohl, MD
Arch Dermatol. 2001;137:930-933.
Background Infliximab is an anti–tumor necrosis factor  monoclonal antibody IgG effective in the treatment and maintenance of remission of active refractory Crohn disease and associated draining enterocutaneous fistulae. Multiple infusions of infliximab show promising results in patients with rheumatoid arthritis. Currently, there is limited clinical experience with infliximab, and no published reports exist on its use in cutaneous disorders.
Observations We describe 2 patients with Crohn disease and pyoderma gangrenosum and 1 patient with Crohn disease and psoriasis who were treated with infliximab for recalcitrant Crohn fistulae, with concurrent improvement in their skin diseases.
Conclusions These cases suggest that infliximab, a promising therapeutic agent for refractory Crohn disease and fistulae, may also be effective in the treatment of pyoderma gangrenosum and psoriasis associated with Crohn disease.
From the Departments of Dermatology (Drs Tan, Gordon, and M. G. Lebwohl) and Gastroenterology (Dr George), The Mount Sinai School of Medicine of New York University, and Division of Gastroenterology, Columbia-Presbyterian Medical Center (Dr O. Lebwohl), New York, NY.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Adalimumab Treatment for Pyoderma Gangrenosum
Heffernan et al.
Arch Dermatol 2007;143:306-308.
FULL TEXT
Pyoderma gangrenosum masquerading as dermatitis artefacta.
Harries et al.
Arch Dermatol 2006;142:1509-1510.
FULL TEXT
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
Brooklyn et al.
Gut 2006;55:505-509.
ABSTRACT
| FULL TEXT
Advances in Psoriasis
Lebwohl
Arch Dermatol 2005;141:1589-1590.
FULL TEXT
Important cutaneous manifestations of inflammatory bowel disease
Trost and McDonnell
Postgrad. Med. J. 2005;81:580-585.
ABSTRACT
| FULL TEXT
Infliximab for the Treatment of Adult-Onset Pityriasis Rubra Pilaris
Liao and Mutasim
Arch Dermatol 2005;141:423-425.
FULL TEXT
Severe Hidradenitis Suppurativa Treated With Infliximab Infusion
Adams et al.
Arch Dermatol 2003;139:1540-1542.
FULL TEXT
Clinical research helps elucidate the role of tumor necrosis factor-{alpha}in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes
Gottlieb
Lupus 2003;12:190-194.
ABSTRACT
|
